Pfizer gains rights to Medivation Alzheimer's drug

NEW YORK (Reuters) - Pfizer Inc is acquiring rights to a promising experimental drug for Alzheimer's disease from Medivation Inc for as much as $725 million, sending Medivation shares up nearly 31 percent. 2 months ago